With a High Risk or a History
of Cardiovascular Disease
Study Overview
The AstraZeneca “AZURE-Outcomes” study is testing a potential new oral, once a day, drug to learn whether it can help lower bad cholesterol and reduce the risk of heart and blood vessel disease in adults who:
- Have a history of heart disease OR
- Have blood vessel disease OR
- Are at high risk for a first cardiovascular event, such as heart attack, stroke, or circulatory issues in the legs.
Qualified Participants May Receive:
- Reimbursement for their travel
- Study-related care at no cost.
Who Can Participate In The AZURE-Outcomes Study?
People With a Prior Cardiovascular Event:
People Who Have NOT Had a Cardiovascular Event, But Are at High Risk:
Who Can Participate In The AZURE-Outcomes Study?
People With a Prior Cardiovascular Event:
People Who Have NOT Had a Cardiovascular Event, But are at High Risk:
What Should I Expect?
Screening Visit
Before you begin the study drug, AZD0780, or placebo, you will complete screening – including consent, medical history, and testing to determine if the study is right for you.
Randomization Visit
Participants are randomly assigned (50/50) to receive either the investigational study tablet or a matching placebo with no active medicine.
Treatment Phase
Should you qualify, your participation may last up to ~4.5 years. You’ll take either Investigational study drug (AZD0780) or matching placebo alongside your regular cholesterol medication. Participation is voluntary, and you can stop taking it at any time.